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Nitric oxideHydrogen sulﬁde (H2S) has been known for hundreds of years because of its poisoning effect. Once the basal
bio-production became evident its pathophysiological role started to be investigated in depth. H2S is a gas
that can be formed by the action of two enzymes, cystathionine gamma-lyase and cystathionine beta-
synthase, both involved in the metabolism of cysteine. It has several features in common with the other two
well known “gasotransmitters” (nitric oxide and carbon monoxide) in the biological systems. These three
gasses share some biological targets; however, they also have dissimilarities. For instance, the three gases
target heme-proteins and open KATP channels; H2S as NO is an antioxidant, but in contrast to the latter
molecule, H2S does not directly form radicals. In the last years H2S has been implicated in several
physiological and pathophysiological processes such as long term synaptic potentiation, vasorelaxation, pro-
and anti-inﬂammatory conditions, cardiac inotropism regulation, cardioprotection, and several other
physiological mechanisms. We will focus on the biological role of H2S as a molecule able to trigger cell
signaling. Our attention will be particularly devoted on the effects in cardiovascular system and in
cardioprotection. We will also provide available information on H2S-donating drugs which have so far been
tested in order to conjugate the beneﬁcial effect of H2S with other pharmaceutical properties.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Hydrogen sulﬁde (H2S) has been known for hundreds of years as a
poisoning and toxic pollutant. It is a colorless gas with a high solubility
in water. H2S is permeable to plasma membranes as its solubility in
lipophilic solvents is ﬁvefold greater than in water. Therefore, the gas
can easily diffuse through the cells and reach intracellular compart-
ments. In the literature several massive intoxications are reported and
in the non-scientiﬁc literature poisoning by this gas is referred to as
“sulphuratted hydrogen” intoxications. These fatal episodes often
occurred in sewers and swamps as the main biological source is
represented by anaerobic bacterial digestion of organic substrates [1]
but it is also produced through inorganic reactions in volcanic gases,
natural gas and well waters [2]. Chemical and enzymatic transforma-
tion of the sulfur compounds of foodstuff such as mushrooms, garlic
and onions are also responsible for H2S production in human gut [3].
High concentrations of H2S lead to the inhibition of mitochondrialiche e Biologiche, Universita' di
assano (TO), Italy. Tel.:+39 011
ardi).
ll rights reserved.electron transport chain at the level of cytochrome oxidase c
representing a high impact occupational and environmental hazard
[4]. In fact, while low micromolar doses can reversibly bind the
cytochrome c, acute H2S poisoning may lead to death through
respiratory paralysis and pulmonary edema. These conditions are
often reported in autopsies of individuals killed by hydrogen sulﬁde
poisoning [5]. In the organism H2S is rapidly oxidized to elemental
sulfur, sulfur oxide (SO2), and sulfates such as sulfuric acid or it can be
hydrolyzed to hydrosulﬁde and sulﬁde ions [6].
At physiological pHs in an aqueous solution, about one third of H2S
remains undissociated. In recent years the biological role of H2S has
been re-evaluated because of its low dose effects on eukaryotic cells.
In mammalian cells low levels of H2S are detected with different
technical approaches including colorimetric assay and polarographic
probes and recently the order of magnitude of basal H2S concentration
has been reset to low nanomolar range [7,8]. Interestingly, it was
already reported in the past that low doses of the potentially
dangerous hydrogen sulﬁde could be of some beneﬁts in the
balneologic treatment of hypertension with thermal and mud baths
[9,10]. However, only in the last years the non-toxic action of H2S
started to be investigated in depth. Although early evidence of a basal
production of H2S in animal tissue were published almost a century
865D. Mancardi et al. / Biochimica et Biophysica Acta 1787 (2009) 864–872ago [11] only recently it has been demonstrated that H2S is produced
as a side product by constitutively expressed enzymes involved in the
metabolism of cysteine: cystathionine beta-synthase (CBS) and
cystathionine gamma-lyase (CSE) [12–14] (Fig. 1). Moreover, H2S
donors as well as inhibitors of the basal production have been tested
in different experimental models showing surprising data about its
physiological role with different experimental approaches (Table 1).
In this review we summarize the literature about the biological
properties of hydrogen sulﬁde with particular interest on the
cardiovascular effects and the potential role in cardioprotection. We,
ﬁnally, overview the recent ﬁndings about novel H2S-donating drugs
that started to be tested on animal model and in vitro experimental
settings.
2. Biological effects
Unfortunately, the best known effect of this gas with a character-
istic smell of rotten eggs is the binding to cytochrome c oxidase which
is responsible for its toxicity [15]. This enzyme catalyzes the oxidation
of ferrocytochrome c by oxygen which represents the terminal
acceptor of the electron transport chain in mitochondria. It can
therefore interacts with other gaseous molecules such as carbon
monoxide (CO), nitric oxide (NO), hydrogen cyanide (HCN), and H2S
[16]. Yet, akin NO, H2S can behave either as a substrate or inhibitor of
cytochrome c oxidase [17,18] leading to the oxidation of the gaseous
molecule and the reduction of the enzyme. Nevertheless, the
mitochondrial enzyme inhibition of the gas is non-competitive to
the binding of cytochrome c with oxygen [19]. Inevitably, the reaction
is coupled with oxygen consumption and with the formation of ferrylFig. 1. Enzymatic pathways of H2S production in mammalian cells. On the left panel the cy
formation of H2S in mitochondria from cysteine. MAT: methionine adenosyltransferase. GN
lyase. AAT: aspartate aminotransferase. MPST: 3-mercaptopyruvate sulfur transferase.enzyme intermediates [19]. The degree of mitochondrial impairment
changes according to experimental settings also depending on the
tissues and species considered: in intact cells mitochondrial respira-
tion is decreased of 50% by 30 μMH2S [20] whereas 10 μM is sufﬁcient
to half-inhibit respiration of isolated mitochondria [21]. Interestingly,
low concentrations (b20 μM) of sodium hydrosulﬁde (NaSH)
stimulate mitochondrial oxygen consumption and augment mem-
brane potential, while higher concentrations inhibit cytochrome c
oxidase lowering oxygen consumption [22]. It is still not clear whether
endogenously produced H2S could signiﬁcantly inhibit respiration in
vivo. The idea that H2S could be of some physiological importance
arose when it became clear that it was naturally produced in several
organisms by constitutively expressed enzymes and that it is present
in mammalian blood at nanomolar concentration [7]. The normal
blood level of H2S is reported to be between∼10 μM inWistar [23] and
∼50 μM in Sprague–Dawley rats [24]. In different tissues higher levels
of H2S are detected: for example in brain tissue concentrations
ranging ∼50–160 μM are reported [25]. However, in contrast with NO,
which is generated from both from endothelial and smooth muscle
cells (SMCs), it is not clear whether H2S is produced only in SMCs [24]
or in both endothelium and SMCs as later reported [26]. In fact, no
evidence of the presence of CSE has been detected in rat aortic
endothelium by RT-PCR [24] whereas signiﬁcant levels of CSE have
been reported in two immortalized endothelial cell lines [26].
Among the biological effects described in the literature several
ﬁndings concern the Central Nervous System in which the main
source on H2S is CBS. However, recent data indicate that enzymatic
production by 3-mercaptopyruvate sulfurtransferase maintains ele-
vate H2S levels in CBS−/−mice brain [27]. Abe and Kimura postulatedtosolic pathway leading to the formation of H2S from methionine. On the right panel
MT: glycine N-methyltransferase. CBS: cystathionine β-synthase. CSE: cysthationine γ-
Table 1
Effects of H2S donors on different experimental settings.
The cell type, the experimental model, the concentration of H2S, the main effect, and the bibliographic reference number are reported.
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hippocampus [28]. The same group showed later that H2S acts
synergistically with NO in inducing vasorelaxation of ileum, portal
vein and thoracic aorta [25]. In a model of isolated porcine irides H2S
reverses carbachol-induced contraction while has no effect on basal
contraction [29]. Moreover, inhibition of KATP channels with 100–
300 μMglibenclamide blocks H2S action on pre-constricted irides [29].
Thus, this report demonstrates the involvement of intracellular [K+] in
mediating H2S-induced SMCs relaxation. As regards to gene regulation
H2S has been reported to regulate expression of cytochrome c oxidase,
vascular endothelial growth factor (VEGF), insulin-like growth factor
(IGF) and receptors for TGF-β [30]. Because of its action on KATP
channels H2S inhibits pancreatic insulin secretion decreasing ATP
levels and thus opening the KATP channels in INS-1E cells [31].
3. H2S as the novel gasotransmitter
The arising ﬁndings on the biological properties stimulated several
groups toward the research on the mechanism of action of H2S and
very soon it was entitled as the third “gasotransmitter” besides NO
and CO because of the biochemical similarities with the “siblings”
molecules. These three molecules share diffusibility through biologi-
cal membranes, biological effects at low doses and toxicity at high
concentrations. Alike NO and CO hydrogen sulﬁde's bimodal activity
does not require a receptor to initiate the intracellular signaling. The
main physiological effects of gasotransmitters are mediated by the
bound to hemoglobin. The three gaseous molecules are produced at
different basal concentrations by constitutively expressed enzymes
[32]: CO is produced by heme oxygenase (HO), H2S by CSE and CBS
while NO is formed by the activity of the three isoforms of Nitric Oxide
Synthase (nNOS, eNOS, iNOS). As regards to the substrates CO is
formed through the metabolism of heme groups to biliverdin while
the activity of NOSs is prevalently based on the metabolism of L-
arginine. CBS and CSE are probably not the only enzymes able to form
H2S in mammalian tissue but the proposed alternative enzymatic
sources have limited physiological relevance [33]. The two main
enzymes involved in the production of H2S are two pyridoxal 5′-
phosphate-dependent enzymes with a preferential expression of CBS
in the CNS and CSE in liver, kidney and blood vessels with a decreasing
activity in tail artery, aorta and mesenteric arteries respectively [34].
CBS catalyzes the reaction of L-serine and L-homocysteine to L-
cystathionine and H2O through a β-replacement between L-serine, L-cysteine, cysteine thioethers and other β-substituted α-L-amino acids
and mercaptans. The replacement of serine by cysteine leads to the
formation of H2S instead of H2O (Fig. 1). CSE catalyzes the conversion
of L-cystathionine into L-cysteine, 2-oxobutanoate and NH3 and, as a
side activity, induces the elimination of L-homoserine forming H2O, 2-
oxobutanoate and NH3. CSE can also react with L-cystine, producing
thiocysteine, pyruvate and NH3, and with L-cysteine producing
pyruvate, NH3 and H2O [35]. Despite of the toxicity at high
concentration CO has been reported to play a physiological role in
regulating synaptic transmission and vascular function at low doses
[36,37]. It has also been shown that inhibition of cytochrome c oxidase
by CO can result in mitochondrial Reactive Oxygen Species (ROS)
production and exert anti-inﬂammatory effect [38]. NO physiological
activities have been widely investigated and data unequivocally show
a key role in the regulation of vascular tone, platelet aggregation,
smooth muscle relaxation, and synaptic function. Some authors
suggest a potential role as gasotransmitter for hydrogen cyanide as
well but this hypothesis will require further investigation to be
conﬁrmed [16]. The three gasotransmitters have been demonstrated
to be synaptic modulator without having conventional receptors on
the membrane of communicating neurons [39]. The endogenously
produced gases diffuse through vessels wall and hemoglobin is
thought to be a common target for CO, NO, and H2S forming
respectively carboxyhemoglobin [40], nytrosylhemoglobin [41], and
sulfhemoglobin [42]. It appears, therefore, clear that the biological
behavior of hydrogen sulﬁde has a lot in common with the two
gaseous transmitter so far identiﬁed [32]. Interestingly, NO and H2S
might collaborate in regulating the vascular homeostasis although
unequivocal results about the interplay of the two molecules are still
lacking. Some authors reported a synergistic effect of H2S in NO-
induced vasodilation [34] whereas others reported the contrary [25].
It has been shown that sodium nitroprusside induces over-expression
of H2S generating enzymes in rat vascular tissues suggesting an
increased H2S production NO-mediated [43]. Moreover, H2S seems to
have a potent antioxidant effect scavenging peroxynitrite and
ameliorating cultured neuronal cell survival after ONOO− challenge
[44]. NO and H2S might also interact at molecular level forming a yet
unidentiﬁed nitrosothiol with potential physiological relevance as
suggested by Whiteman et al. [45].
The normo-physiological levels of H2S in the blood are reported to
range from 10 to 300 μMwith the exception of one study reporting the
value of 5 μM measured with a polarographic probe [46]. However,
867D. Mancardi et al. / Biochimica et Biophysica Acta 1787 (2009) 864–872sulﬁde concentrations of whole blood, plasma, or BSA decay as its
consumption is proportional to protein concentration but indepen-
dent from oxygen partial pressure as demonstrated by saturationwith
N2 that does not affect decay rate [47]. It has been suggested that
blood levels of H2S are undetectable in the vertebrate using amodiﬁed
polarographic sensor [47]. In order to address H2S presence in
different tissues exogenous H2S absorption has been tested in
homogenates of brain, heart and liver showing that brain absorption
is much slower than those of heart and liver [48]. The vasorelaxant
effect of H2S has been demonstrated in different experimental models
although it is not clear whether it is produced at the endothelial level.
The effect on vessels seems to be dependent on oxygen concentration
[46] and vasodilation is partially mediated by the opening of KATP
sensitive channels at least in some vascular districts [24]. In fact, the
gas can easily diffuse through SMCs and increase the K+ permeability
leading to hyperpolarization and relaxation of SMCs. In vivo, an
intravenous bolus injection of H2S determines a transient fall in blood
pressure that can be mimicked by the KATP channel opener Pinacidil
[24]. However, the in vivo hypotensive effect might be also attributed
to an inhibition of Angiotensin-Converting-Enzyme as it has recently
been shown [49]. Endogenous formation of H2S from CSE contributes
to maintain normal blood pressure as demonstrated in CSE−/− mice
that show higher systemic pressure compared to the wild type
animals thus suggesting a pivotal contribution of this enzyme for the
normal vessels tone [26]. At the vascular level the beneﬁcial effect of
H2S is also based on a marked decrease in neutrophil adhesion. H2S
contributes also to reduce vascular inﬁltration acting as an anti-
inﬂammatory agent [50]. This effect can be reversed in a model of
hemorrhagic shock where the anti-inﬂammatory response can be
turned into a pro-inﬂammatory effect [51]. Sodium hydrosulﬁde
relaxant action was also shown in an in vitro model of pregnant rat
uterus strips where it induced signiﬁcant decreases in uterine
spontaneous contractility in a dose-dependent manner [52] (Table 1).
4. Hydrogen sulﬁde and the cardiovascular system
Although deﬁnitive evidence supporting the hypothesis of a basal
enzymatic production of H2S are still questioned the contribution of
H2S to the cardiovascular homeostasis is gaining more signiﬁcance
[26]. In the past H2S was believed to impair the cardiovascular
function relatively to its toxic effect [53]. However, the role of
hydrogen sulﬁde in maintaining the vascular tone is nowadays well
established. It was at ﬁrst demonstrated that exogenously applied
NaSH could induce relaxation in smooth muscle of rat thoracic aorta
[25] and subsequently that in vivo administration of H2S induces a
transient but signiﬁcant fall in blood pressure [24]. Therefore,
experimental data suggest that the hypotensive effect of H2S is a
consequence of the relaxation of blood vessels SMCs triggered by
opening of KATP channels increasing K+ currents and hyperpolarizing
membrane of SMCs of peripheral vessels [24]. Also in an ex vivomodel
of human internal mammary artery rings NaSH was effective in
inducing relaxation. It has also been shown that in Spontaneous
Hypertensive Rats (SHRs) production of H2S is markedly decreased in
the thoracic aorta. Hypertension in these animals can be reversed by
exogenous H2S administration which also leads to a decrease in
vascular collagen accumulation [54] (Table 1). However, endogenous
H2S was showed to regulate basal tone by inhibition of CSE with DL-
propargylglycine [55]. This was the ﬁrst report on the presence and on
the activity of H2S generating enzymes in humans. In contrast with
NO, H2S vasorelaxant effect is not mediated by soluble guanylyl
cyclase (sGC) as demonstrated by the inhibition of sCG with ODQ
which does not prevent H2S-induced vasorelaxation [24]. It is also
likely that this effect is mediated by inward Ca2+ currents and by an
increase of intracellular Ca2+ concentration [34]. In an in vitro model
of perfused rat mesenteric artery beds (MABs) either NaSH or bubbled
H2S solution induce a signiﬁcant relaxation proportionally with theconcentration though the results are different when compared to data
obtained in rat aortic tissue [56]. In fact, NaHS vasodilates the pre-
contracted MABs but the extent of relaxation is signiﬁcantly lower
than that of bubbled H2S solution [56]. Therefore, it is reasonable to
believe that the fall in blood pressure observed by several authors is
dependent on the general relaxation of peripheral resistance blood
vessel which is well represented by MABs [56].
4.1. H2S as a preconditioning agent
Although more than twenty years have passed since its ﬁrst
description, ischemic preconditioning (IP) still remains one of the
most potent cardioprotective mechanism against ischemia/reperfu-
sion (I/R) injury [57]. It consists of brief sub-lethal episodes of
ischemia conferring protection against a subsequent prolonged
ischemic insult. Several triggers, mediators and effectors of IP have
been so far identiﬁed [58,59]. Among the others NO and its redox
sibling molecule HNO− have also been proven to induce cardioprotec-
tion in the isolated rat heart [60] despite of the contradictory
dynamics of NO [41] and the orthogonal properties of the two
molecules [61]. Both classical ischemic preconditioning and NO-
induced cardioprotection is mediated by the opening of mitochondrial
KATP channels, PKCɛ translocation, and ROS production [62]. Since all
of these mediators are also activated by H2S a potential role in IP for
the third gasotransmitter can be suggested (Fig. 2). The hypothesis
that H2S can function as a preconditioning agent is also supported by
the fact that respiratory inhibition with this gas is different from
hypoxia. In fact, while oxygen deprivation leads to massive cell loss,
H2S induces suspended animation which confers protection against
potentially lethal hypoxia [63]. Suspended animation is a fascinating
phenomenon consisting in lowering metabolic rate and increasing
resistance to low oxygen concentration pretreating mice with H2S
[64]. However, these studies are unique and H2S has been shown to be
protective against myocardial ischemia/reperfusion injury only when
given before hypoxia [65]. An increasing number of studies provide
evidence that both exogenous and endogenous H2S exert protective
effects against myocardial I/R injuries in different experimental
settings [66–69]. NaSH pre-treatment signiﬁcantly reduces cardio-
myocytes death after in vitro I/R simulation and attenuates both
duration and scores of arrhythmias during the initial 10 min of
reperfusion after a low-ﬂow ischemia in isolated rat hearts [70].
Accordingly to these data, NaSH shows beneﬁcial effects in Langen-
dorff-perfused hearts after a 30 min left coronary artery ligation
followed by 120 min reperfusion [68]. Further support to the
hypothesis that H2S could play a pivotal role as a preconditioning
agent is provided by in vivomodels of I/R inwhich pre-treatment with
sodium hydrosulﬁde triggered the so called second window of
protection [69]. Thus, being the late preconditioning phase initiate
by protein expression H2S can also regulate gene transcription (Fig. 1).
In this study it was also proved that the action of hydrogen sulﬁde is
mediated by mitochondrial KATP sensitive channels. In fact, 5-
hydroxydecanoate (5-HD) was used instead of glibenclamide ensur-
ing a selective blockage of mitochondrial population of KATP channels
[69]. However, it is not clear whether H2S-induced cardioprotection
involves NO release and/or the mediation of PKC [71]. Interestingly,
H2S was proved to be effective also in the protection against hepatic
I/R injury in a mouse model inhibiting the progression of apoptosis
and increasing the expression of heat shock protein-90 (HSP-90) and
Bcl-2 [72]. Similar results concern the cytoprotective effect of NaSH
against oxidative stress on a cardiac cell line. In this model H2S
upregulates mitochondrial Bcl-2 and activates the Akt pathway [73].
The cardioprotective effect of H2S donors is conﬁrmed by an in vivo
murine model of pharmacological preconditioning with IK1001
which confers protection against ischemic injury in term of decrease
in infarct size, serum troponin-I levels, and oxidative stress [74].
Moreover, IK1001 induces up-regulation of Trx-1 and Trx-2, increased
Fig. 2. Proposed signaling pathways of H2S in cardioprotection: representation of the putative cascade of reactions triggered by molecular H2S. The yellow solid line indicates the direct inhibitory pathway to the β-adrenergic receptors and the
dashed yellow line indicates the indirect inhibitory action on L-type Ca2+ channels. Red lines: direct activation of membrane andmitochondrial KATP channels with consequent activation/translocation of PKC. Black lines represent mechanism
of early and late cardioprotection (SWOP). NCX: Na+/Ca2+ exchanger. SERCA: Sarco/Endoplasmatic Reticulum Ca2+-ATPase. RyR: Ryanodine Receptor. PKC: Protein Kinase C. PKA: Protein Kinase A. AC: Adelynate Cyclase. ROS: Reactive Oxygen
Species. ETC: electron transport chain. mPTP: mitochondrial Permeability Transition Pore. SWOP: second window of protection.
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869D. Mancardi et al. / Biochimica et Biophysica Acta 1787 (2009) 864–872expression of HSP-90, HSP-70, Bcl-2, and Bcl-xL suggesting a potential
mediation of antioxidant and anti-apoptotic signaling in the
cytoprotective mechanisms [74]. The same group proposed that
both endogenous and exogenous H2S can be useful in the treatment
of heart failure using a transgenic mouse model in which the
constitutive expression of CSE was upregulated in the heart [75]. Both
in the transgenic mice and in IK1001 treated mice structural and
functional deterioration of left ventricle were reduced and perfor-
mance preserved after occlusion of the left coronary artery [75].
Consistently with these results, administration of Na2S improves
resuscitation after cardiac arrest in mice and this effect is probably
due to cell survival signaling pathway as suggested by phosphoryla-
tion of Akt and caspase-3 activation [76].
5. H2S and redox state
The chemical dynamic of H2S is strictly related to the redox state of
cells. In physiological conditions at 37 °C and at pH 7.4 around 82.5% is
present in the form of HS− and a small amount of S2− while the rest
remains undissociated. However, taking in considerations the pKa1 of
the reaction (6.755) the level of H2S at standard conditions (20 °C, pH
7.4) is signiﬁcantly higher (30%) [77,78]. Under acidic conditions acid-
labile sulfur can be released by the iron–sulfur core of mitochondrial
enzymes and it has been measured in brain tissue of rats, bovines, and
humans [79–81]. On the other hand, physiological pH of mitochondria
is too high to facilitate acid-labile sulfur release by this kind of storage
[48]. Another form of storage is represented by the so called bound
sulfur in the cytosolic fraction and H2S can be released under reducing
conditions [82]. Olson's group proposed a model in which constitu-
tively produced H2S diffuses from cytoplasm to mitochondriawhere it
is rapidly oxidized [83]. The amount of H2S being oxidized is therefore
proportional to the oxygen partial pressure (pO2) and biologically
available H2S is the result of production minus oxidation [8].
Moreover, CBS and CSE activity is inﬂuenced by the redox environ-
ment [84,85] thus contributing to regulate intracellular concentration
of H2S. Recently, a mitochondrial pathway for sulﬁde oxidation has
been described in two different models [86]. In the mitochondrial
matrix of rat liver and body-wall tissue of Arenicola marina, a sulfur
dioxygenase converts persulﬁde to sulﬁte with consumption of
oxygen. The persulﬁdes are produced by sulﬁde by quinone oxido-
reductase and a second molecule of persulﬁde is added by sulfur
transferase leading to the formation of thiosulfate [86]. Interestingly,
H2S consumption in puriﬁed mitochondria is increased when O2 is
added and decreasedwhenmitochondria are either denatured by heat
or gassed with nitrogen [8]. In neurons H2S protective effect against
oxidative stress is mediated by increased glutathione (GSH) concen-
tration and by activating KATP and Cl− channels [87]. Therefore, the
antioxidant role of H2S seems to be mainly effective through
intracellular GSH formation which buffers the redox imbalance.
However, it has been shown that H2S increases mRNA levels of
heme oxygenase-1 and it may act synergistically with CO in regulating
vascular structural remodeling [88]. The ability of H2S to counteract
redox imbalance has also been shown in aspirin-induced gastric
toxicity [89]. In this model, the same pathway seems to mediate the
antioxidant effect of H2S involving GSH formation, HO-1 up-regula-
tion, and isoprostane synthesis inhibition.
6. Pharmacological implications
Recently, an increasing number of diseases have been related to an
imbalance of endogenous H2S production [35]. The endogenous
release of H2S from mammalian tissues is likely to occur in a slow
and constant rate and it appears to be involved in several processes
such as neuromodulation [28], hypertension [90], inﬂammation
[33,91], hemorrhagic shock [92] and edema [93]. Pharmacological
studies are either focused on the regulation of basal production of H2Sor to investigate the role of exogenously applied donors. Until now, the
majority of H2S donors used for biological researches have been
restricted to sulﬁde salts. The most commonly used is NaHS, which
have a fast releasing rate in aqueous solution producing one third of
hydrogen sulﬁde compared to the concentration of the salt. However,
to mimic the naturally occurring enzymatic release the researchers
focused on organic compounds able to release the gasotransmitter
over a prolonged period of time. In this contest, a novel water-soluble
compound (GYY4137) was reported to slowly release H2S both in vitro
and in vivo after being injected intravenously or intraperitonealy in
anesthetized rats [94]. In these set of experiments it was demon-
strated that GYY4137 acts as vasodilator and antihypertensive both in
normal and spontaneously hypertensive rats [94]. The increasing
volume of data regarding physiological and pathophysiological effects
of hydrogen sulﬁde suggest future implications for sulﬁde-related
compounds in the treatment of hypertension and ischemic patholo-
gies. Pharmacological studies are also directed towards the inhibition
of H2S production and/or H2S donors. In fact, an inhibitor of
phosphodiesterase 5 (Sildenaﬁl) was conjugated with an H2S
releasing group and tested on pulmonary artery endothelial cells
[95]. The H2S-donating derivative of Sildenaﬁl (ACS6) releases more
H2S than NaSH because of the three sulfur atoms bound to the
molecule and the delivery rate reaches the peak after 2 h [95]. It was
shown that superoxide formation is inhibited by hydrogen sulﬁde and
that ACS6 can also increase cAMP representing a potential treatment
for respiratory distress syndrome [95]. Another type of hydrogen
sulﬁde releasing moiety was tested on smooth muscle cells: an H2S-
releasing derivative of the nonsteroidal anti-inﬂammatory drug,
diclofenac (S-diclofenac) inhibited cell proliferation and the authors
postulated a potential role in the treatment of vascular occlusive
disorders [96]. With other perspectives, S-diclofenac was used to
revert the potentially lethal gastrointestinal toxicity of NSAIDs
showing an enhanced anti-inﬂammatory activity and a diminished
gastrointestinal toxicity [97]. Moreover, sulﬁde releasing sartans are
reported to be cytoprotective against oxidative stress induced by
hydrogen peroxide when compared to the non-sulfurate molecule
[98]. Consistently, in the same cell line the effect of 30 μM of H2S
induces an up-regulation of the Akt-GSK3β-ERK 1/2 pathway and the
activation of Bcl2 with an anti-apoptotic effect [73]. Therefore, pro-
survival and anti-apoptotic pathways might be activated simulta-
neously leading to an increased cell survival after oxidative stress. In
another study, a new dithiolethione-containing aspirin (ACS14) was
tested on rats showing inhibition of thromboxane comparable to
aspirin while prostacyclin formation was decreased [89]. Thus, ACS14
maintains beneﬁcial effects of parent compoundwhereas it appears to
be less detrimental for the gastrointestinal mucosa. Interestingly, in an
animal model of diabetes inhibition of H2S production by pancreatic
islets lowered glycemia and increased serum level of insulin
supporting the hypothesis that insulin release is impaired because
of abnormal pancreatic production of H2S [99]. It was also found that
NaSH exerts an anti-atherogenic effect downregulating ICAM-1
expression in a transgenic mouse model and the results is supported
by data obtained in human umbilical vein endothelial cells (HUVECs)
[100]. In fact, in HUVECs treated with NaSH ICAM-1 expression is
suppressed via the NF-kβ pathway [100]. In rainbow trout endogen-
ous hydrogen sulﬁde contributes to adrenergic stimulation enhancing
catecholamine secretion in a Calcium-dependent manner [101]. In an
avian model has been demonstrated that ventilation with high doses
of hydrogen sulﬁde induces an increase of CO2 pulmonary receptors
drive to the central respiratory neurons [102]. This effect is probably
mediated by inhibition of carbonic anhydrase [102]. Hydrogen sulﬁde
decreases oxygen demand as demonstrated by longer survival of mice
exposed to 5% oxygen when pre-treated with H2S [63]. This condition
is useful in ischemic/hypoxic tissues treatment. In fact, the possibility
of protecting myocytes against hypoxia/reoxygenation injuries has
been proved in vitro [71], ex vivo [68], and in vivo models [69,103]
870 D. Mancardi et al. / Biochimica et Biophysica Acta 1787 (2009) 864–872reducing both necrosis and apoptosis. The mechanism of action is
probably related to the opening of the KATP channels as demonstrated
by the loss of protectionwith co-infusion of channel blockers [69,103].
Further investigation reported an involvement of the ERK-AkT
pathway in sulﬁde-preconditioned rat heart and a role of H2S in the
classical preconditioning [104]. At the level of the gastrointestinal
tract the enterobacterial ﬂora is responsible for the production of H2S.
However, excessive entry of sulﬁde in the circulation and potential
toxicity on intestinal epithelium is prevented by regulatory enzymes
activity [3,105]. Vascular production of H2S has been related to
endotoxin-induced inﬂammation [106] and it was later demonstrated
that higher rate of H2S production corresponds to an up-regulation of
CSE expression in liver and kidney [107].
7. Conclusion
Despite of the early clues of some beneﬁcial effects hydrogen
sulﬁdehas beenneglected for a long time as a potential biological actor.
Neither its high diffusibility nor its strong ability to bind respiratory
enzymes served to stimulate studies about its physiological role until
recent years. On the other hand only when modern tools, such as
polarographic probes, have replaced non-speciﬁc colorimetric techni-
ques used to determine sulﬁde concentrations it became possible to
detect the basal concentration. The basal endogenous presence of H2S
suddenly stimulated the scientiﬁc community to investigate the
biological dynamics of this molecule with evident similarities to NO
and CO. It was soon demonstrated that H2S has a lot in common with
the other two gasotransmitters both in terms of chemical activities and
biological targets [32]. In the last years H2S have been implicated in
long term synaptic potentiation [28], vasorelaxation [25], pro- and
anti-inﬂammatory processes [50,51], cardiac inotropism regulation
[108], cardioprotection [66,68,69], and several other physiological
processes [35,44,99,100]. Beneﬁts fromH2Smight also be attributed to
its antioxidant properties and in contrast with NO it does not form
radicals directly [44,109]. Nevertheless, it is clear that H2S plays a
pivotal role in the basal regulation of vessels tone aswell as other basic
process such as neuromodulation and inﬂammation. Contemporarily,
novel H2S-donating drugs have been tested in order to conjugate the
beneﬁcial effect of H2S with other pharmaceuticals [66,73,89,95,96].
However, a deﬁnite agreement on the concentrations level in different
tissues is still lacking. Yet it is uncertain the ability of blood to transport
and deliver sulﬁdes. Further studies are also required in order to
establish the mechanisms of action of this extremely diffusible
molecule in different cell types. So far only the a role for plasmalemmal
and mitochodrial K+ channel activation has been unequivocally
demonstrated as a part of H2S's activity on cells [69]. Electrophysio-
logical variations as well as ionic channels activity are still to be
elucidated to better understand the effect of H2S on excitable tissues.
Finally, but not of less importance, the picture of all the potential
biochemical reactions is still foggy and it needs to be clariﬁed for a
sufﬁcient comprehension of the possible interactions of sulﬁdes with
plasma proteins and intracellular enzymes.
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